153 related articles for article (PubMed ID: 11159506)
21. Antiphospholipid antibodies in children without and in adults with and without thrombophilia.
Siemens HJ; Gutsche S; Brückner S; Bucsky P; Katus HA
Thromb Res; 2000 May; 98(4):241-7. PubMed ID: 10822070
[TBL] [Abstract][Full Text] [Related]
22. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
Loew A; Jacob D; Neuhaus P; Riess H
Transplantation; 2005 May; 79(10):1422-7. PubMed ID: 15912114
[TBL] [Abstract][Full Text] [Related]
23. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
[TBL] [Abstract][Full Text] [Related]
24. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
J Thromb Haemost; 2014 Nov; 12(11):1801-9. PubMed ID: 25196808
[TBL] [Abstract][Full Text] [Related]
25. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.
Galli M; Duca F; Ruggeri L; Finazzi G; Negri B; Moia M
Thromb Haemost; 1998 Aug; 80(2):246-9. PubMed ID: 9716147
[TBL] [Abstract][Full Text] [Related]
26. Activated protein C resistance in antiphospholipid thrombosis syndrome.
Wu J; Zhou Z; Li X; Li X; Chen Y; Wang G; Wang Z
Chin Med J (Engl); 2000 Aug; 113(8):699-701. PubMed ID: 11776051
[TBL] [Abstract][Full Text] [Related]
27. Thromboembolism in paediatric lupus patients.
Levy DM; Massicotte MP; Harvey E; Hebert D; Silverman ED
Lupus; 2003; 12(10):741-6. PubMed ID: 14596422
[TBL] [Abstract][Full Text] [Related]
28. [Activated protein C resistance as a cause of thrombophilia].
Ruiz-Argüelles GJ
Rev Invest Clin; 1996; 48(3):223-9. PubMed ID: 8966383
[TBL] [Abstract][Full Text] [Related]
29. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients.
Formiga F; Mitjavila F; Pac M; Moga I
Lupus; 1997; 6(5):486. PubMed ID: 9229372
[No Abstract] [Full Text] [Related]
30. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
31. Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II.
Simmelink MJ; Fernández JA; Derksen RH; Griffin JH; de Groot PG
Br J Haematol; 2002 Jun; 117(3):676-84. PubMed ID: 12028041
[TBL] [Abstract][Full Text] [Related]
32. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
33. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
34. Non-criteria manifestations in the presence of antiphospholipid antibodies in a paediatric cohort.
Morán-Álvarez P; Andreu-Suárez Á; Caballero-Mota L; Gassiot-Riu S; Berrueco-Moreno R; Calzada-Hernández J; Antón-López J; Vázquez-Díaz M; Boteanu A
Rheumatology (Oxford); 2022 Nov; 61(11):4465-4471. PubMed ID: 35137009
[TBL] [Abstract][Full Text] [Related]
35. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
[TBL] [Abstract][Full Text] [Related]
36. Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Ames PR; Pyke S; Iannaccone L; Brancaccio V
Thromb Haemost; 1995 May; 73(5):768-73. PubMed ID: 7482401
[TBL] [Abstract][Full Text] [Related]
37. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?
Galli M
Haemostasis; 2000; 30 Suppl 2():57-62. PubMed ID: 11251342
[TBL] [Abstract][Full Text] [Related]
38. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
39. Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Staropoli JF; Van Cott EM; Makar RS
Transfusion; 2008 Nov; 48(11):2435-41. PubMed ID: 18673345
[TBL] [Abstract][Full Text] [Related]
40. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.
Wahl DG; Guillemin F; de Maistre E; Perret C; Lecompte T; Thibaut G
Lupus; 1997; 6(5):467-73. PubMed ID: 9229367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]